2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 3101

Lipoprotein Profile and Serum Glycoprotein Acetylation As Markers of Cardiovascular Risk in Systemic Lupus Erythematosus
Abstract Number: 1495

Lipoprotein(a) Concentrations in Rheumatoid Arthritis on Biologic Therapy: Results from the Cardiovascular in Rheumatology [CARMA] Study Project
Abstract Number: 480

Local Cryotherapy Down-Regulates Local and Systemic IL-6/IL-17 Pathway with No Effect on TNF-α in Adjuvant-Induced Arthritis
Abstract Number: 2070

Long Noncoding RNA H19X Is a Master Regulator of Extracellular Matrix Production in Systemic Sclerosis and Other Fibrotic Disease
Abstract Number: 2550

Long Persistence of Anti-Drug Antibodies in Adalimumab Treated RA Patients
Abstract Number: 2482

Long Term Drug Survival of Adalimumab and Etanercept Treatment for Rheumatoid Arthritis with and without Methotrexate
Abstract Number: 876

Long Term Efficacy of Ustekinumab for the Treatment of Giant Cell Arteritis
Abstract Number: 2852

Long Term Prognosis of Lupus Nephritis in the Afro-Caribbean Population of Martinique with Free Access to Healthcare
Abstract Number: 302

Long-Lasting Local Knee Structural Pathology Is Associated with Persistent Multi-Site Pain
Abstract Number: 1713

Long-Term (156-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of 3 Phase III, Randomized, Controlled Trials
Abstract Number: 725

Long-Term Anti-TNF Treatment Is Associated with Reduction of Progression of Radiographic Changes in the Sacroiliac Joints in Patients with Non-Radiographic Axial Spa: Six-Year Results of the Esther Trial
Abstract Number: 1648

Long-Term Clinical, Radiographic and Patient-Reported Outcomes Based on RAPID3 Responses with Tofacitinib at 6 Months
Abstract Number: 7

Long-Term Dietary Changes after Rheumatoid Arthritis Diagnosis in Swedish Women: Data from a Population Based Cohort
Abstract Number: 732

Long-Term Effect of TNF Inhibitors on Radiographic Progression in Ankylosing Spondylitis Is Associated with Syndesmophytes at Baseline and Time-Averaged CRP Levels
Abstract Number: 389

Long-Term Effectiveness and Safety of Abatacept in Juvenile Idiopathic Arthritis: Interim Results from the Abatacept in JIA Registry

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].